| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/21/2009 | US20090131331 Novel Nutraceutical Compositions |
| 05/21/2009 | US20090131330 Par-2 agonist |
| 05/21/2009 | US20090131329 Treatment for allograft rejection |
| 05/21/2009 | US20090131328 Furin inhibitors |
| 05/21/2009 | US20090131327 Nogo receptor functional motifs and peptide mimetics related thereto and methods of using the same |
| 05/21/2009 | US20090131326 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131325 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131324 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131323 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131322 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131321 Method of reducing injury to mammalian cells |
| 05/21/2009 | US20090131320 Peptides modulating the activity of the engrailed transcription factor |
| 05/21/2009 | US20090131319 Protein of given amino acid sequence; heterologous polypeptide comprises Fc portion of antibody molecule; identifying agonists and antagonists; diagnosis and treatment of disease resulting from aberrant cell proliferation |
| 05/21/2009 | US20090131318 Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| 05/21/2009 | US20090131317 Compounds and peptides that bind the trail receptor |
| 05/21/2009 | US20090131316 Glucagon-like peptide-1 secretagogue, glucagon-like peptide-1 secretagogue food or drink, inhibitor of postprandial rise in blood glucose, and inhibitory food or drink of postprandial rise in blood glucose |
| 05/21/2009 | US20090131315 Treatment of Subarachnoid Hemorrhage With APO E Analogs |
| 05/21/2009 | US20090131314 Thrombospondin-1 Derived Peptides and Treatment Methods |
| 05/21/2009 | US20090131313 Lkktet and/or lkktnt peptide compositions and methods for treating or preventing tissue deterioration, injury or damage |
| 05/21/2009 | US20090131312 Non-natural chemokine receptor ligands and methods of use thereof |
| 05/21/2009 | US20090131311 Method for Preventing Formation of Trisulfide Derivatives of Polypeptides |
| 05/21/2009 | US20090131310 Mucin3 egf-like domains |
| 05/21/2009 | US20090131309 Ica512 couples insulin secretion and gene expression in beta-cells |
| 05/21/2009 | US20090131308 Splice Variants of ErbB Ligands, Compositions and Uses Thereof |
| 05/21/2009 | US20090131307 Pharmaceutical compositions comprising cyclosporins |
| 05/21/2009 | US20090131306 Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor |
| 05/21/2009 | US20090131305 Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases |
| 05/21/2009 | US20090131304 Semi-Synthetic Desmethyl-Vancomycin-Based Glycopeptides With Antibiotic Activity |
| 05/21/2009 | US20090131303 Methods and compositions for treating dry eye |
| 05/21/2009 | US20090131302 Transient receptor potential vanilloid 1 and uses thereof |
| 05/21/2009 | US20090131277 Prostate cancer diagnosis and treatment |
| 05/21/2009 | US20090130737 Novel fungal proteins and nucleic acids encoding same |
| 05/21/2009 | US20090130733 Method for producing non-infectious products from infectious organic waste material |
| 05/21/2009 | US20090130695 Isolated nucleic acid encoding GEF-H1b polypeptide (Guanine nucleotide exchange factors); diagnosing abnormal cell proliferation and drug screening; measuring phosphorylation by p-21 activated kinase; antitumor agents, anticancer agents |
| 05/21/2009 | US20090130692 Use of microproteins as tryptase |
| 05/21/2009 | US20090130681 21132, a Human G-protein coupled receptor family member and uses therefor |
| 05/21/2009 | US20090130674 Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
| 05/21/2009 | US20090130228 Pharmaceutical combination for the treatment and or chemosensibilization of refractory tumors to anticancer drugs |
| 05/21/2009 | US20090130216 Multimodal particulate formulations |
| 05/21/2009 | US20090130204 Dosage Form Comprising Therapeutic Formulation |
| 05/21/2009 | US20090130198 Pharmaceutical composition with enhanced bioavailability |
| 05/21/2009 | US20090130192 Class iii slrp agonists for the reduction of blood vessel formation |
| 05/21/2009 | US20090130191 Osteoclast Growth Inhibitor, Oral Composition, and Preventive or Therapeutic Agent for Bone Diseases, Containing Liposome-Encapsulated Lactoferrin |
| 05/21/2009 | US20090130185 Anti-Microbial Compositions Comprising a Cationic Peptide and a Glycylglycine Endopeptidase |
| 05/21/2009 | US20090130174 Poly (ester urethane) urea foams with enhanced mechanical and biological properties |
| 05/21/2009 | US20090130141 Compositions and methods for stimulating an immune response against infectious agents |
| 05/21/2009 | US20090130130 Mutant allergen(s) |
| 05/21/2009 | US20090130122 Methods for treating rheumatoid arthritis using IL-17 antagonists |
| 05/21/2009 | US20090130121 Synthetic Peptide Copolymers for Treatment and Prevention of Cardiovascular Disorders |
| 05/21/2009 | US20090130116 Use of CEACAM8-Specific Substances for Treating Autoimmune Diseases and a Method for Screening Substances Which Induce Apoptosis |
| 05/21/2009 | US20090130112 Spatial for altering cell proliferation |
| 05/21/2009 | US20090130109 DCL-1 and uses thereof |
| 05/21/2009 | US20090130107 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 05/21/2009 | US20090130098 Specific therapy using integrin ligands for treating cancer |
| 05/21/2009 | US20090130097 Quinazolinone Compounds and Methods of Use Thereof |
| 05/21/2009 | US20090130095 Composition comprising tumor necrosis factor (CD40) specific immunoglobulin for treatment and prevention of autoimmune diseases |
| 05/21/2009 | US20090130092 Nucleotide phosphate dissipation as a treatment for vascular disorders |
| 05/21/2009 | US20090130087 Method for measuring the content of a botulinum toxin in a formulation |
| 05/21/2009 | US20090130086 FXIII Variants with Improved Properties |
| 05/21/2009 | US20090130085 Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations |
| 05/21/2009 | US20090130084 Tagged IgA1 proteases |
| 05/21/2009 | US20090130083 Therapeutic Agents Targeting the NCCA-ATP Channel and Methods of Use Thereof |
| 05/21/2009 | US20090130082 Compositions and methods for the treatment and prevention of infections caused by staphylococcus aureus bacteria |
| 05/21/2009 | US20090130081 Method for treating pervasive development disorders |
| 05/21/2009 | US20090130080 Reducing blood glucose level in a non-obese or obese human afflicted with Type 2 diabetes by administering purified human placental alkaline phosphatase |
| 05/21/2009 | US20090130079 Intraventricular enzyme delivery for lysosomal storage diseases |
| 05/21/2009 | US20090130078 Treatment for Cardiovascular Disease |
| 05/21/2009 | US20090130075 Energy generating composition |
| 05/21/2009 | US20090130070 Method of treatment |
| 05/21/2009 | US20090130067 Cell Population Having Immunoregulatory Activity, Method for Isolation and Uses |
| 05/21/2009 | US20090130062 Novel Application of Heparin-Binding Epidermal Growth Factor-Like Growth Factor for Medical Purposes |
| 05/21/2009 | US20090130060 Modified Vitamin K Dependent Polypeptides |
| 05/21/2009 | US20090130059 Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| 05/21/2009 | US20090130058 Biologically active composition comprising ethylcellulose |
| 05/21/2009 | US20090130057 Compounds for the Treatment of Hepatitis C |
| 05/21/2009 | US20090130056 Compounds for the Treatment of Hepatitis C |
| 05/21/2009 | US20090130055 Use of a Cytokine From the Interleukin-6 Family In the Preparation of a Composition For Combined Administration With Interferon-Alpha |
| 05/21/2009 | US20090130054 Apc activators in combination with a cytokine-secreting cell and methods of use thereof |
| 05/21/2009 | US20090130034 Re-engineered uv damage endonuclease, compositions and methods |
| 05/21/2009 | US20090130021 Methods, products and uses involving platelets and/or the vasculature |
| 05/21/2009 | US20090130017 Targeted short-lived drug delivery |
| 05/21/2009 | US20090127112 Biologically active metal-coated proteins |
| 05/21/2009 | US20090126732 Dry powder inhalation system for transpulmonary administration |
| 05/20/2009 | EP2060918A2 Breast endothelial cell expression patterns |
| 05/20/2009 | EP2060634A1 Structure protein of adeno-associated virus with amended antigenity, production and application thereof |
| 05/20/2009 | EP2060630A2 PCA3, PCA3 genes, and methods of use |
| 05/20/2009 | EP2060586A1 New synthetic arginine substituted peptides and their use |
| 05/20/2009 | EP2060585A2 Gene regulatory peptides |
| 05/20/2009 | EP2060581A1 Scaffold proteins for recombinant peptide aptamers |
| 05/20/2009 | EP2060268A1 Pharmaceutical compositions for pulmonary or nasal delivery of peptides |
| 05/20/2009 | EP2060267A2 Methods for therapy of neurodegenerative disease of the brain |
| 05/20/2009 | EP2060266A1 Y4 selective receptor agonists for therapeutic interventions |
| 05/20/2009 | EP2060265A2 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 05/20/2009 | EP2060253A1 Pharmaceutical forms for the release of active compounds |
| 05/20/2009 | EP2059806A2 Modified annexin proteins and methods for their use in platelet storage and transfusion |
| 05/20/2009 | EP2059606A2 Fusion peptide therapeutic compositions |
| 05/20/2009 | EP2059598A1 Compositions and methods for modulating ampa receptor-mediated excitotoxicity |
| 05/20/2009 | EP2059594A1 Neukinase, a downstream protein of neuregulin |
| 05/20/2009 | EP2059593A2 Treating or preventing cancers over-expressing reg4 or kiaa0101 |
| 05/20/2009 | EP2059587A2 Laccases for pulp bio-bleaching |